Phyteau is developing a new class of therapeutics for diabetes, obesity, weight-loss, and related metabolic condition like NAFLD and NASH. The company's therapeutics work in the intestines where they trigger key cellular receptors causing the release of therapeutic levels of key metabolic hormones, like GLP-1, PYY and CCK. The hormones work